Information  X 
Enter a valid email address

Marlborough Intnl Fd (IRSH)

  Print      Mail a friend

Thursday 11 October, 2018

Marlborough Intnl Fd

Changes to the Board

RNS Number : 7703D
Marlborough Intnl Fund PCC Ltd
11 October 2018
 

COMPANY ANNOUNCEMENT

 

 

For Immediate Release

11 October 2018

 

 

Marlborough International Fund PCC Limited

 

 

RE: Changes to the Board

                                                                                         

 

The Board of Directors (the "Board") of Marlborough International Fund PCC Limited (the "Company") wishes to announce that with effect from 9 October 2018, Mr Kevin Gilligan resigned from the Board.  In addition, Mr Jason Le Roux has been appointed to the Board. 

 

Mr Le Roux was appointed as a Director of the Administrator Louvre Fund Services Limited in 2016. Mr Le Roux previously held the position of Managing Director of Dominion Fund Management Limited. Prior to that Mr Le Roux was Custody Manager and Client Relationship Manager at HSBC Custody Services (Guernsey)  Limited and spent 6 years with the Credit Suisse Group of companies in both London and Guernsey.  Mr Le Roux is an Associate of The Chartered Institute of Securities & Investment and a member of the Institute of Directors.

 

Mr Le Roux has been appointed as an independent non-executive director of the Fund.

 

Save as disclosed herein, no further information is required to be disclosed in relation to Mr Le Roux under the Irish Stock Exchange, trading as Euronext Dublin's ("Euronext Dublin") listing requirements for investment funds.

 

 

Enquiries:

 

 

 

Matheson

Yvonne Lappin

Phone: +353 1 232 2000

 

 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEMBBBTMBTBBRP

a d v e r t i s e m e n t